Friday, December 12, 2025 2:32:40 PM
BioForce makes the most sense to me based on quick reads and their affiliation with University of Pittsburgh. Here's one online description I read about BioForce:
Key Players & Opportunities in Pittsburgh:
University of Pittsburgh (Pitt) & ElevateBio: This major partnership is building the BioForge Biomanufacturing Center, a large facility for cell/gene therapy development and manufacturing, attracting other biotechs and creating a central hub.
This is what ElecateBio says about itself:
We’re building the future of medicine by combining two essential capabilities: gene editing technologies and the expertise to manufacture complex therapies at scale. Through partnerships with biopharma companies, we provide the tools, facilities, and knowledge needed to develop genetic medicines faster and more efficiently, accelerating their delivery to patients worldwide.
Here's another quote from them:
We are more than a traditional CDMO at ElevateBio BaseCamp®. We are a skilled partner offering the expertise, technologies, and state-of-the-art facilities to provide manufacturing solutions for cell and gene therapies, from preclinical through commercial production.
I don't think gene editing fits with DCVax technology, but it appears they have state-of-the-art facilities for large-scale manufacturing.
Also, it appears that BioForce is recruiting companies to set up shop with them, so perhaps NWBO future includes creating its own GMP space there. But that's just me speculating into the future.
This trail of posts include a URL that lists over 40 cell and gene therapy companies, so please look through them to see if any of these companies could have synergy with DCVax. Maybe one of them would look like a more likely site for NWBO to put down roots in the US.
Also remember, NWBO is talking about continuing clinical trials and research on DCVax-Direct and the in-licensed technology for Roswell and U. of Pitt at this US site. I have suggested here that this clinical work gives us a foothold toward eventual commercialization but, again, that's just me thinking into the future.
This is the most recent November 2025 10K:
Manufacturing in the US for In-licensed Technologies. Based upon further assessments of the two candidate GMP manufacturing locations in the US which the Company had previously narrowed down to as finalists, the Company finalized its selection and undertook contract negotiations to secure the selected location and to allocate operational responsibilities. The Company continued the hiring process for personnel with the special types of expertise and prior experience needed for the initial core operating team for this location.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
RENI Completes Due Diligence on Target Acquisition; Confirms Strong Asset Base and Operational Performance • RENI • Mar 5, 2026 10:15 AM
BlackStar Engages in Talks with U.S. Senate Banking Committee Team Covering the Digital Asset Market Clarity Act • BEGI • Mar 4, 2026 4:47 PM
